Table 1.
Patient characteristics before and after propensity score matching
| Before matching | After matching | |||||
| Statin (+) | Statin (−) | Standardised difference | Statin (+) | Statin (−) | Standardised difference | |
| n=1065 | n=1523 | n=936 | n=936 | |||
| Preprocedural variables | ||||||
| Age, years | 84.1±5.0 | 84.6±5.3 | 0.01 | 84.2±5.0 | 84.3±5.2 | 0.01 |
| Men, n (%) | 322 (30.2) | 473 (31.1) | 0.02 | 277 (29.6) | 255 (27.2) | 0.05 |
| Body surface area, m2 | 1.44±0.17 | 1.42±0.17 | 0.13 | 1.44±0.17 | 1.43±0.17 | 0.07 |
| NYHA class 3 or 4, n (%) | 518 (48.6) | 803 (52.7) | 0.08 | 462 (49.4) | 457 (48.8) | 0.01 |
| Clinical Frailty Scale | 3.8±1.2 | 4.1±1.3 | 0.23 | 3.8±1.2 | 3.8±1.2 | 0.04 |
| Diabetes mellitus, n (%) | 264 (24.8) | 291 (19.1) | 0.14 | 207 (22.1) | 195 (20.8) | 0.03 |
| Smoking, n (%) | 212 (19.9) | 260 (17.1) | 0.07 | 169 (18.1) | 160 (17.1) | 0.02 |
| Hypertension, n (%) | 861 (80.9) | 1129 (74.1) | 0.16 | 744 (79.5) | 753 (80.5) | 0.02 |
| Chronic kidney disease, n (%) | 755 (70.9) | 1054 (69.2) | 0.04 | 651 (69.6) | 640 (68.4) | 0.03 |
| Atrial fibrillation, n (%) | 195 (18.3) | 354 (23.2) | 0.12 | 181 (19.3) | 183 (19.6) | 0.01 |
| Coronary artery disease, n (%) | 507 (47.6) | 447 (29.4) | 0.38 | 378 (40.4) | 372 (39.7) | 0.01 |
| Previous myocardial infarction, n (%) | 108 (10.1) | 50 (3.3) | 0.28 | 48 (5.1) | 48 (5.1) | <0.01 |
| Previous percutaneous coronary intervention, n (%) | 342 (32.1) | 284 (18.7) | 0.31 | 249 (26.6) | 238 (25.4) | 0.03 |
| Previous coronary artery bypass grafting, n (%) | 112 (10.5) | 57 (3.7) | 0.27 | 60 (6.4) | 57 (6.1) | 0.01 |
| Peripheral artery disease, n (%) | 161 (15.1) | 216 (14.2) | 0.03 | 136 (14.5) | 128 (13.7) | 0.02 |
| Previous stroke, n (%) | 127 (11.9) | 174 (11.4) | 0.02 | 116 (12.4) | 102 (10.9) | 0.05 |
| STS risk score | 7.7±6.0 | 8.6±7.5 | 0.13 | 7.7±6.1 | 7.7±5.3 | <0.01 |
| Renin-angiotensin inhibitor, n (%) | 639 (60.0) | 748 (49.1) | 0.22 | 540 (57.7) | 544 (58.1) | 0.01 |
| ß blocker, n (%) | 384 (36.1) | 496 (32.6) | 0.07 | 334 (35.7) | 303 (32.4) | 0.07 |
| eGFR, mL/min/1.73 m2 | 51.7±18.5 | 51.1±20.1 | 0.03 | 52.3±18.6 | 51.7±19.6 | 0.03 |
| Haemoglobin, g/L | 114±17 | 111±17 | 0.17 | 114±17 | 112±16 | 0.15 |
| LDL-c, mg/dL | 104.3±28.9 | 94.2±28.0 | 0.35 | 105.9±28.2 | 94.8±27.8 | 0.4 |
| HDL-c, mg/dL | 52.9±15.8 | 53.6±15.0 | 0.04 | 53.5±16.3 | 54.3±15.0 | 0.05 |
| Triglyceride, mg/dL | 106.8±57.6 | 110.5±53.0 | 0.07 | 109.6±60.9 | 110.2±53.2 | 0.01 |
| Preprocedural echocardiographic data | ||||||
| Aortic valve area, cm2 | 0.64±0.17 | 0.63±0.17 | 0.04 | 0.63±0.17 | 0.63±0.16 | <0.01 |
| Indexed aortic valve area, cm2/m2 | 0.44±0.12 | 0.44±0.12 | <0.01 | 0.44±0.12 | 0.45±0.12 | 0.03 |
| Mean aortic gradient, mm Hg | 50.0±18.1 | 51.0±18.4 | 0.05 | 51.0±18.2 | 50.8±18.2 | 0.01 |
| Peak velocity, m/s | 4.5±0.8 | 4.6±0.8 | 0.07 | 4.6±0.8 | 4.6±0.8 | 0.02 |
| Ejection fraction, % | 59.2±12.7 | 59.2±12.6 | <0.01 | 59.6±12.4 | 59.7±12.0 | 0.01 |
| Severe aortic regurgitation, n (%) | 12 (0.8) | 4 (0.4) | 0.05 | 7 (0.8) | 4 (0.4) | 0.04 |
| Severe mitral regurgitation, n (%) | 21 (1.4) | 12 (1.1) | 0.02 | 12 (1.3) | 6 (0.6) | 0.07 |
| Pulmonary hypertension, n (%) | 40 (3.8) | 62 (4.1) | 0.02 | 37 (4.0) | 33 (3.5) | 0.02 |
| Preprocedural CT data | ||||||
| Annular area, mm2 | 395.5±70.7 | 400.7±71.0 | 0.07 | 395.9±70.2 | 396.5±69.1 | 0.01 |
| Procedural variables | ||||||
| Transfemoral approach, n (%) | 873 (82.0) | 1294 (85.0) | 0.08 | 770 (82.3) | 784 (83.8) | 0.04 |
| Local anaesthesia, n (%) | 799 (75.0) | 1179 (77.4) | 0.06 | 714 (76.3) | 734 (78.4) | 0.05 |
| Contrast volume, mL | 115.8±59.1 | 115.4±58.0 | 0.01 | 118.8±60.0 | 113.5±57.1 | 0.09 |
| Fluoroscopy time, min | 21.7±12.5 | 21.1±10.0 | 0.05 | 21.9±12.6 | 21.0±10.0 | 0.08 |
| Procedure time, min | 81.6±45.8 | 80.3±45.4 | 0.03 | 81.6±43.0 | 80.4±43.6 | 0.03 |
eGFR, estimated glomerular filtration rate; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons.